N803

Phase 2Small molecule

SSt. Jude Children's Research Hospital

N803 is one of 124 small molecule programs targeting Immunodeficiency. It is currently in Phase 2.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyActive, not recruiting

Neuroblastoma RecurrentRecruiting

Prostate CancerNot yet recruiting

LymphomaNot yet recruiting

ImmunodeficiencyPhase 1

Active, not recruiting

Neuroblastoma RecurrentPhase 2

Recruiting

Prostate CancerPhase 1

Not yet recruiting

LymphomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

N803

SSt. Jude Children's Research Hospital

Phase 2

2 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Lymphoma

NCT05618925

Q1 2029

Phase 2Recruiting

Neuroblastoma Recurrent

NCT07085338

Q1 2031

Phase 1Not yet recruiting

Prostate Cancer

NCT07756593

Q4 2031

Phase 1Not yet recruiting

Lymphoma

NCT07049432

Clinical

Trials by Indication[1]

Lymphoma2 trials

N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Not yet recruiting·UUniversity of Utah·Phase 1·NCT07049432·13 enrolled

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Recruiting·IImmunityBio, Inc.·Phase 1·NCT05618925·20 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT04247282·21 enrolled

Prostate Cancer1 trial

A Phase Ib Study Evaluating the Safety and Tolerability of Sipuleucel-T (Sip-T) in Combination With N-803 in Patients With Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07756593·30 enrolled

Neuroblastoma Recurrent1 trial

A Phase II Study With a Safety Run-In of the Addition of N-803, a Novel IL-15 Super-Agonist, to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT07085338·54 enrolled

Unspecified1 trial

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Active, not recruiting·RRockefeller University·Phase 1·NCT05245292·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for N803. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N803 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N803. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSt. Jude Children's Research Hospital

N803

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2029

Q1 2031

Q4 2031

Trials by Indication[1]

Lymphoma2 trials

Head and Neck Squamous Cell Carcinoma1 trial

Prostate Cancer1 trial

Neuroblastoma Recurrent1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News